Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the female sexual dysfunction (FSD) drug market will grow 10% from 2002 to 2007. According to the new Pharmacor study entitled Female Sexual Dysfunction, the launch of drugs specifically approved for FSD will drive the market. Currently, no drugs are approved to treat the disease.

"Of all drugs in development for FSD, three transdermal testosterone formulations, Procter & Gamble's Intrinsa, Cellegy's Tostrelle, and BioSante's LibiGel, show the most promise," said David Lapidus, analyst at Decision Resources. "The launches of these drugs, starting with Intrinsa in 2004, will prompt a wave of marketing that will likely raise awareness of FSD."

The study also finds that experts expressed concern that physicians' attitudes toward FSD are a "disaster", or even "medieval". Both doctors and the public will require education about FSD before they are willing to treat or discuss the disorder.

About Female Sexual Dysfunction

FSD is a chronic disease typically caused by hormonal imbalances or psychogenic factors. Nearly 100 million women suffer from FSD in the seven major pharmaceutical markets (United States, France, Germany, Spain, Italy, Japan, and the United Kingdom), but only a tiny fraction currently receive drug therapy. This complex condition, which has surprised many experts in its dissimilarity to erectile dysfunction, offers vast opportunities for the pharmaceutical industry.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Female Sexual Dysfunction is a Mosaic study.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for more than 30 years, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.DecisionResources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

New Report Reveals Pockets Of Growth in HMO Market

View Now